Sandhya Srinivas

TL;DR: Overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus among patients with previously treated advanced renal-cell carcinoma.

TL;DR: The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivorumab as a new standard of care across a broad range of patients with previously treated aRCC.

TL;DR: Sunitinib 37.5 mg, administered on a continuous once-daily dosing regimen, has a manageable safety profile as second-line mRCC therapy, providing flexible dosing, which can be explored in combination studies.

TL;DR: Nivolumab continues to be better than everolimus in extending the lives of patients, providing a long-lasting response to treatment, and improving quality of life with a manageable safety profile, and this supports the long-term benefits of nivolumsab monotherapy in patients with previously treated aRCC.

TL;DR: It is found that the MagSweeper effectively isolated CTCs with a capture efficiency that matched the CellSearch platform, and mRNA-Seq analysis showed that any perturbations caused by the Mag Sweeper process on the transcriptional signature of isolated cells are modest.